• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Surges 150 Points; US Jobless Claims Decline Sharply

    11/22/23 9:43:44 AM ET
    $AGIL
    $ATHE
    $EIGR
    $GES
    Professional Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIL alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones index gaining around 150 points on Wednesday.

    Following the market opening Wednesday, the Dow traded up 0.43% to 35,239.40 while the NASDAQ rose 1% to 14,342.66. The S&P 500 also rose, gaining, 0.63% to 4,566.74.

    Check This Out: Top 5 Materials Stocks That May Rocket Higher In November

     

    Leading and Lagging Sectors

     

    Communication services shares surged by 1.2% on Wednesday.

    In trading on Wednesday, energy shares fell by 1.7%.

     

    Top Headline

     

    U.S. initial jobless claims declined by 24,000 to 209,000 on the week ending Nov. 18, compared to market expectations of 225,000.

     

    Equities Trading UP

     

    AgileThought, Inc. (NASDAQ:AGIL) shares shot up 129% to $0.1901 after gaining 5% on Tuesday.

    Shares of SciSparc Ltd. (NASDAQ:SPRC) got a boost, shooting 23% to $7.81 after the company announced it signed a non-binding letter of intent to merge with a vehicle importer company in Israel.

    Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shares were also up, gaining 19% to $0.37.

     

    Equities Trading DOWN

     

    Nogin, Inc. (NASDAQ:NOGN) shares dropped 18% to $0.3117 after jumping 21% on Tuesday.

    Shares of Alterity Therapeutics Limited (NASDAQ:ATHE) were down 18% to $1.9409.

    Guess?, Inc. (NYSE:GES) was down, falling 13% to $20.56 after the company reported worse-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance below estimates.

    Also Check This Out: Jim Cramer Calls Major Automaker Stock A 'Wait And See Situation' — 'I Want To See The Quarter'

     

    Commodities

     

    In commodity news, oil traded down 2.7% to $75.65 while gold traded up 0.1% at $2,004.10.

    Silver traded up 0.2% to $23.91 on Wednesday while copper fell 0.9% to $3.7785.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 gained 0.3%, London’s FTSE 100 fell 0.2% while Spain’s IBEX 35 Index rose 0.4% The German DAX rose 0.4% French CAC 40 climbed 0.4%, while Italy’s FTSE MIB Index rose 0.3%.

    Passenger car registrations in the European Union jumped 14.6% year-over-year to 855.5 thousand units for October. The UK’s public sector net borrowing, excluding banks, came in at £14.9 billion for October, compared to £10.5 billion in the year-ago month. Labor productivity in the UK declined 0.2% on quarter during the third quarter versus a 0.7% rise in the prior period.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Wednesday, with Japan’s Nikkei 225 gaining 0.29%, Hong Kong’s Hang Seng Index rising 0.01% and China’s Shanghai Composite Index falling 0.79%. India’s S&P BSE Sensex, meanwhile, rose 0.14%.

    Singapore's current account surplus narrowed to SGD 30.07 billion in the third quarter from SGD 32.73 billion in the year-ago period. Singapore’s GDP increased by 1.1% year-over-year in the third quarter following 0.5% growth in the prior quarter.

     

    Economics

     

    U.S. initial jobless claims declined by 24,000 to 209,000 on the week ending Nov. 18, compared to market expectations of 225,000.

    U.S. durable goods orders fell by 5.4% month-over-month in October following a 4.0% increase in September.

    Now Read This: How To Earn $500 A Month From Guess? Stock Following Q3 Earnings Report

    Get the next $AGIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIL
    $ATHE
    $EIGR
    $GES

    CompanyDatePrice TargetRatingAnalyst
    Guess? Inc.
    $GES
    8/21/2025$13.00 → $16.75Market Perform
    Telsey Advisory Group
    Guess? Inc.
    $GES
    3/26/2025$18.00 → $13.00Market Perform
    Telsey Advisory Group
    Alterity Therapeutics Limited
    $ATHE
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    Alterity Therapeutics Limited
    $ATHE
    12/12/2024$8.00Buy
    Maxim Group
    Guess? Inc.
    $GES
    11/27/2024$21.00 → $18.00Market Perform
    Telsey Advisory Group
    Guess? Inc.
    $GES
    8/29/2024$26.00 → $21.00Market Perform
    Telsey Advisory Group
    Guess? Inc.
    $GES
    5/31/2024$30.00 → $26.00Market Perform
    Telsey Advisory Group
    Guess? Inc.
    $GES
    3/21/2024$23.00 → $30.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $AGIL
    $ATHE
    $EIGR
    $GES
    SEC Filings

    View All

    SEC Form EFFECT filed by SciSparc Ltd.

    EFFECT - SciSparc Ltd. (0001611746) (Filer)

    2/13/26 12:15:18 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    2/12/26 4:02:11 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    2/4/26 4:01:15 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $ATHE
    $EIGR
    $GES
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Guess? with a new price target

    Telsey Advisory Group reiterated coverage of Guess? with a rating of Market Perform and set a new price target of $16.75 from $13.00 previously

    8/21/25 7:57:07 AM ET
    $GES
    Apparel
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on Guess? with a new price target

    Telsey Advisory Group reiterated coverage of Guess? with a rating of Market Perform and set a new price target of $13.00 from $18.00 previously

    3/26/25 7:44:43 AM ET
    $GES
    Apparel
    Consumer Discretionary

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $ATHE
    $EIGR
    $GES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

    NeuroThera's Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the United States Patent and Trademark Office has granted a U.S. patent for NeuroThera's proprietary combination of antimicrobials and cannabinoids. This patent covers innovative compositions and method

    2/2/26 8:24:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

    SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the closing of the acquisition of an IP portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo"). The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat

    1/26/26 8:13:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $ATHE
    $EIGR
    $GES
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kayne Richard A bought $72,815 worth of shares (278,239 units at $0.26) (SEC Form 4)

    4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

    11/2/23 9:21:30 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kawas Leen bought $6,375 worth of shares (24,332 units at $0.26) (SEC Form 4)

    4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)

    11/2/23 9:14:42 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIL
    $ATHE
    $EIGR
    $GES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Michael Elsa disposed of $371,532 worth of shares (22,181 units at $16.75), closing all direct ownership in the company (SEC Form 4)

    4 - GUESS INC (0000912463) (Issuer)

    1/27/26 9:59:38 PM ET
    $GES
    Apparel
    Consumer Discretionary

    Director Chidoni Anthony disposed of $3,879,400 worth of shares (231,606 units at $16.75), closing all direct ownership in the company (SEC Form 4)

    4 - GUESS INC (0000912463) (Issuer)

    1/27/26 9:56:41 PM ET
    $GES
    Apparel
    Consumer Discretionary

    Chairman of the Board Yemenidjian Alex disposed of $3,402,428 worth of shares (203,130 units at $16.75), closing all direct ownership in the company (SEC Form 4)

    4 - GUESS INC (0000912463) (Issuer)

    1/27/26 9:53:21 PM ET
    $GES
    Apparel
    Consumer Discretionary

    $AGIL
    $ATHE
    $EIGR
    $GES
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Winmark Set to Join S&P SmallCap 600

    NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Winmark Corp. (NASD: WINA) will replace Guess? Inc. (NYSE:GES) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 26. Authentic Brands Group LLC and the Rolling Stockholders are acquiring Guess? in a deal expected to close soon pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Jan 26, 2026 S&P SmallCap 600 Addition Winmark WINA Consumer Discretionary Jan 26, 2026 S&P SmallCap 600 Deletion Guess? GES Consumer Discretionary ABOUT S&P DOW JONES INDICES S&P Dow Jone

    1/21/26 6:01:00 PM ET
    $GES
    $SPGI
    $WINA
    Apparel
    Consumer Discretionary
    Finance: Consumer Services
    Finance

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $ATHE
    $EIGR
    $GES
    Financials

    Live finance-specific insights

    View All

    Authentic and Guess? Co-Founders Maurice and Paul Marciano Complete Transaction to Take Guess? Private

    With This Landmark Deal, Authentic Now Owns 51% of Guess? IP and the Remaining 49% is Owned by the Guess? Rolling Shareholders Current Guess? Management Owns 100% of the Operating Company Authentic Brands Group (Authentic), a global brand development and licensing platform, and Guess?, Inc. (NYSE:GES) today announced they have completed the transaction to take Guess? private. Authentic now owns 51% of substantially all Guess? intellectual property, and existing Guess? shareholders, Maurice Marciano, Paul Marciano, Nicolai Marciano and Carlos Alberini and certain of their respective trusts, foundations and affiliates (collectively, the "Rolling Shareholders"), now own 49% of all Guess? i

    1/23/26 9:01:00 AM ET
    $GES
    Apparel
    Consumer Discretionary

    Guess?, Inc. Reports Fiscal Year 2026 Third Quarter Results

    Revenues Increased to $791 Million, Up 7% in U.S. Dollars and 5% in Constant Currency Delivered Operating Margin of 2.9%; Adjusted Operating Margin of 4.7% GAAP EPS of $0.48 and Adjusted EPS of $0.35 Guess?, Inc. (NYSE:GES) today reported financial results for its third quarter ended November 1, 2025. Carlos Alberini, Chief Executive Officer, commented, "We are pleased with our third quarter performance, with revenue growth of 7% in U.S. dollars and 5% in constant currency, driven by a strong performance of our Americas Wholesale and Europe businesses. In our Americas Retail business, despite continued softness, we were encouraged by the continued improvement in same store sales versus th

    11/25/25 4:15:00 PM ET
    $GES
    Apparel
    Consumer Discretionary

    Guess?, Inc. to Release Third Quarter Fiscal 2026 Financial Results

    Guess?, Inc. (NYSE:GES) will release its financial results for the third quarter of fiscal year 2026, which ended November 1, 2025, on Tuesday, November 25, 2025. The financial results will be accessible at www.guess.com via the "Investor Relations" link. In light of the pending take-private transaction, Guess? will not host a conference call in connection with its quarterly results. Guess?, Inc. designs, markets, distributes and licenses a lifestyle collection of contemporary apparel, denim, handbags, watches, eyewear, footwear and other related consumer products. Guess? products are distributed through branded Guess? stores as well as better department and specialty stores around the

    11/18/25 5:30:00 PM ET
    $GES
    Apparel
    Consumer Discretionary

    $AGIL
    $ATHE
    $EIGR
    $GES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Guess? Inc.

    SC 13D/A - GUESS INC (0000912463) (Subject)

    10/16/24 5:12:20 PM ET
    $GES
    Apparel
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Guess? Inc.

    SC 13D/A - GUESS INC (0000912463) (Subject)

    10/16/24 5:09:48 PM ET
    $GES
    Apparel
    Consumer Discretionary

    SEC Form SC 13G/A filed by Eiger BioPharmaceuticals Inc. (Amendment)

    SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)

    5/10/24 2:14:57 PM ET
    $EIGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care